Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’...

por Charbonneau, C, Sandin, R
Publicado 2010

Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species

por Drgona, L., Khachatryan, A., Stephens, J., Charbonneau, C., Kantecki, M., Haider, S., Barnes, R.
Publicado 2013

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

por Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J
Publicado 2012

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia

por Auzinger, G, Playford, G, Graham, C, Narula, H, Charbonneau, C, Weinstein, D, Kantecki, M, Schlamm, H, Ruhnke, M
Publicado 2013

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis...

por Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J
Publicado 2010